Skip to main content

Recent News

Sjögren’s and SOB? Think About ILD!

Daric A. Mueller, PA-C

ILD is a particularly worrisome systemic feature of SjD that may be associated with poorer quality of life outcomes and increased mortality. Prevalence of SjD-ILD has been quoted to occur in 10-20% of SjD patients; however, identification of SjD may vary widely based on the testing methodologies used.

New FDA Approved for Polymyalgia Rheumatica - Secukinumab

Jack Cush, MD

Today the US Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. This is the first anti-IL-17 biologic approved for people living with PMR. 

A Look Ahead: Precision, Safety and Access as Therapies Grow More Complex

Jiha Lee, MD

ACR Convergence 2026 closed on a high note with the Clinical Year in Preview, a forward-looking session on the final day presented by Alexis Ogdie, MD, MSCE, of the University of Pennsylvania. 

Her aim was to highlight emerging therapies, preview trials expected to report results in 2027, and define the knowledge gaps in clinical rheumatology and  the solutions needed to advance treatment and care.

Dr. John Cush
@RheumNow
Not All Pain in Rheumatic Disease is Inflammatory In a session at the Global Rheumatology Summit, Dr. Daniel Clauw, an expert on the topic, explained that fibromyalgia can occur in isolation in a “top-down” fashion, or can be secondary to inflammatory autoimmune diseases in a https://t.co/AMUm52SKsB
Dr. John Cush
@RheumNow
Two Prescriptions, One Patient Obesity, in particular in PsA was widely covered at #ACR26. In the Swiss SCQM registry, 63.6% of 2,087 patients with PsA were overweight or obese, compared with 31% overweight and 12% obese in the Swiss population, and higher BMI tracked disease https://t.co/Ys5wTvQ2r9
×